#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Cytokine release syndrome Myeloid leukaemia Prostate cancer Enteritis Monogenic diabetes Indolent systemic mastocytosis Extra-osseous Ewing's sarcoma Meningococcal immunisation Mantle cell lymphoma stage II Depression Gastroenteropancreatic neuroendocrine tumour disease Hidradenitis Uterine leiomyosarcoma Chronic kidney disease Hyperinsulinaemic hypoglycaemia More trials…

    Learn about Rare Diseases

    Combined immunodeficiency – Trials in Disease Wiskott-Aldrich syndrome – Trials in Disease Haemophilia B with anti factor IX – Trials in Disease Sjogren’s syndrome – Trials in Disease Gaucher’s disease type III Myelodysplastic syndrome with excess blasts – Basic Information Kearns-Sayre syndrome – Diagnostics Immunodeficiency congenital – Trials in Disease Optic glioma – Trials in Disease Mucopolysaccharidosis II – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Efepoetin Alfa ISPAGHULA HUSK A/(H3N2)-LIKE VIRUS ANTIGEN PEGVISOMANT Rbl007.2 Calcium Levofolinate Favezelimab POLYMYXIN B SULFATE HYALURONIDASE GSKVX000000039711 Dexlansoprazole Etravirine Riluzole Microcrystalline Cellulose Tyrosine Buclizine Hydrochloride SARACATINIB Ace Inhibitors, Plain ADMILPARANT S227928 More therapies…

    Learn about Your Condition

    Cytokine release syndrome Anal abscess Pleural mesothelioma Peripheral artery stenosis Leiomyosarcoma metastatic Follicular lymphoma Oropharyngeal cancer Pulmonary embolism Bone metabolism disorder Obesity Type V hyperlipidaemia Hypercholesterolaemia Diabetic autonomic neuropathy Cholangiocarcinoma Hepatic cancer More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Nervous System Diseases

  • Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis

    Recruiting

    3 1
    Austria Belgium Bulgaria Croatia Czechia Denmark +14

  • Open-Label Extension Study of ATH434-DP2 in Patients with Multiple System Atrophy

    Recruiting

    2 1 1
    Investigated Diseases:
    • Multiple system atrophy
    Investigated Drugs:
    • 5,7-DICHLORO-2-((ETHYLAMINO)METHYL)-8-HYDROXY-3-METHYLQUINAZOLIN-4(3H)-ONE METHANESULFONATE
    France

  • A study to evaluate the efficacy and safety of DYNE-101 in patients with Myotonic Dystrophy Type 1

    Recruiting

    3 1 1
    Investigated Drugs:
    • Humanised Igg1 Kappa Fragment Antibody Targeting Tfr1 Conjugated To P125 Oligonucleotide
    • Sodium Chloride Ph. Eur.
    • Sodium Hydrogen Carbonate Pheur
    Belgium Denmark France Germany Italy The Netherlands +1

  • A study to evaluate the effectiveness and safety of clemizole hydrochloride as an additional treatment for patients with Lennox-Gastaut syndrome

    Recruiting

    3 1
    Investigated Diseases:
    • Lennox-Gastaut syndrome
    Investigated Drugs:
    • Clemizole Hydrochloride
    Czechia Hungary Italy Poland Romania Spain

  • A study using [11C]ORM-13070 to examine the effects of aging and Parkinson’s disease on specific brain receptors.

    Recruiting

    2 1 1
    Investigated Drugs:
    • 1-[[(3S)-2,3-DIHYDRO-1,4-BENZODIOXIN-3-YL]METHYL]-4-[3-((11C)METHOXYMETHYL)-2-PYRIDINYL]PIPERAZINE
    France

  • An exploratory study to evaluate the effect of rimonabant on hand function in patients with cervical spinal cord injury

    Recruiting

    1 1 1
    Investigated Diseases:
    • Spinal cord injury cervical
    Spain
Previous Page
1 2 3 4 … 141
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!